Chronic myeloid leukemia highlights from ASH 2025 include data on nilotinib vs imatinib, asciminib in second line, somatic ...

Shares of Enliven Therapeutics (ELVN) climbed on Thursday after the cancer drug developer posted initial data from a Phase 1b ...

"I know physicians are busy, but I’m treating a patient, not a disease. I take a holistic approach. I think we need to make physicians who treat chronic myeloid leukemia treat the disease and make ...

Shares of Enliven Therapeutics (NASDAQ:ELVN) climbed 7% on Thursday after the company released positive early results from a ...

Scemblix showed a 68% major molecular response rate at 48 weeks, outperforming tyrosine kinase inhibitors by 19%. Common side effects included rash, musculoskeletal pain, and fatigue, with laboratory ...

Shares of Enliven Therapeutics were sharply higher after the biotechnology company reported positive initial data from a Phase 1b trial for a leukemia treatment. The stock was up 61% at $24.95 in ...

"These findings indicate that frailty is a strong independent predictor for adverse in-patient outcomes in hospitalized CML patients . . . Frailty not only poses greater risk for in-hospital death in ...

Enliven Therapeutics' stock rose after early trial results showed strong responses and good safety for its leukemia drug, ...

In the phase 2 FASCINATION trial, researchers sought to improve the rate of major molecular response 4 in patients newly diagnosed with CML.

Tyrosine kinase inhibitors (TKIs) have revolutionized CML treatment, offering more effective and better-tolerated options than previous therapies. Second- and third-generation TKIs address resistance ...

Chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL) are two different types of leukemia. Both conditions affect white blood cells. CML affects a type of white blood cell called ...

Researchers analyzed the diagnostic value of stereotactic brain biopsy in patients with leukemia presenting central ...